Opocrin

Opocrin is a privately held, established leader in the niche but critical market of heparin-based APIs and complex molecules, with deep roots dating back to 1964 and a formal incorporation in 2018. The company has evolved from a research lab into a vertically integrated global player, controlling its supply chain from raw material sourcing in the US, Europe, and China through to manufacturing and global distribution to over 50 countries. Its business model combines the production and sale of its own portfolio of APIs (including heparins, iron complexes, glycosaminoglycans, and pulmonary surfactants) with contract manufacturing and development services for pharmaceutical partners. With a recent Top Employer 2026 certification and significant R&D investments, Opocrin is focused on expanding the therapeutic applications of heparin derivatives beyond anticoagulation.

Expertise in extraction, purification, characterization, and chemical modification of complex biological molecules, particularly glycosaminoglycans like heparin. Platform focuses on creating novel heparin derivatives with dissociated pharmacological activities (e.g., non-anticoagulant heparins) for new therapeutic indications.

Opocrin competes in the global heparin API market with other large manufacturers, including Chinese firms (like Shenzhen Hepalink, Nanjing King-friend) and Western companies (like Bioiberica, Pfizer/Hospira). Its differentiation is based on 60 years of specialized expertise, vertical integration, quality reputation, and its R&D into novel derivatives, moving beyond commodity competition.